Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Annals of Hematology|June 1, 1992
Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host diseaseB Glass, L Uharek, W Gassmann, et al.
Bone Marrow Transplantation|February 1, 1995
Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assayM Salomo, J Steinmann, B Glass, et al.
Leukemia|March 4, 2005
CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targetsO Penack, C Gentilini, L Fischer, et al.
Bone Marrow Transplantation|January 1, 1993
Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation modelL Uharek, B Glass, T Gaska, et al.
Bone Marrow Transplantation|August 26, 1998
Immunotherapeutic aspects of allogeneic peripheral progenitor cellsB Glass, L Uharek, G Hartung, et al.
Bone Marrow Transplantation|January 20, 2009
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCTM Schmidt-Hieber, S Schwarck, A Stroux, et al.
Bone Marrow Transplantation|August 26, 1998
Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF aloneG Hartung, L Uharek, M Zeis, et al.
Leukemia|November 1, 1996
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2L Uharek, M Zeis, B Glass, et al.
International Journal of Hematology|May 22, 2010
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletionMartin Schmidt-Hieber, S Schwarck, A Stroux, et al.
British Journal of Haematology|July 1, 1991
High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potentialW Gassmann, L Uharek, A Erbersdobler, et al.
Pageof 6